OARSI–OMERACT definition of relevant radiological progression in hip/knee osteoarthritis
Paul Ornetti,Kenneth D. Brandt,M. P. Hellio-Le Graverand,Marc C. Hochberg,David J. Hunter,Margreet Kloppenburg,Nancy E Lane,Jean-Francis Maillefert,S.A. Mazzuca,Tim D. Spector,G. Utard-Wlerick,Eric Vignon,Maxime Dougados +12 more
TL;DR: An initiative based on both an Evidence Based Medicine and Expert Opinion approach resulted in a proposal of definition of relevant radiological progression in OA to be used as end-point in clinical trials and also recommendations on the conduct of the reliability study allowing such definition.
read more
About: This article is published in Osteoarthritis and Cartilage. The article was published on 01 Jul 2009. and is currently open access.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.
Timothy E. McAlindon,Michael P. LaValley,William F. Harvey,Lori Lyn Price,Jeffrey B. Driban,Ming Zhang,Robert Ward +6 more
TL;DR: 2 years of intra-articular triamcinolone, compared with intra-artsicular saline, resulted in significantly greater cartilage volume loss and no significant difference in knee pain, and these findings do not support this treatment for patients with symptomatic knee osteoarthritis.
Pharmacologic therapy for osteoarthritis—the era of disease modification
TL;DR: Disease modification is described and some of the challenges involved in the discovery and development of disease-modifying OA drugs (D MOADs) are discussed; specific agents that are beyond preclinical development in phase II and III trials and show promise as potential DMOADs are discussed.
298
The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement
Laure Gossec,Simon Paternotte,J.F. Maillefert,Christophe Combescure,P. G. Conaghan,Aileen M. Davis,K-P Gunther,G.A. Hawker,Marc C. Hochberg,Jeffrey N. Katz,Margreet Kloppenburg,Keith Lim,L.S. Lohmander,Nizar N. Mahomed,Lyn March,Karel Pavelka,L Punzi,Ewa M. Roos,Lidia Sanchez-Riera,Jasvinder A. Singh,Maria E. Suarez-Almazor,Maxime Dougados +21 more
TL;DR: Although symptom levels were higher in patients recommended for TJR, pain and functional disability alone did not discriminate between those who were and were not considered to need TJR by the orthopaedic surgeon.
195
Diabetes is a risk factor for knee osteoarthritis progression.
F. Eymard,Camille Parsons,Mark H. Edwards,F Petit-Dop,Jean-Yves Reginster,Olivier Bruyère,Pascal Richette,Cyrus Cooper,Xavier Chevalier +8 more
TL;DR: Type 2 diabetes was a predictor of joint space reduction in men with established knee OA and no relationships were found between MetS or other metabolic factors and radiographic progression.
190
Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative.
Chao Zeng,Chao Zeng,Nancy E Lane,David J. Hunter,Jie Wei,Jie Wei,Hyon K. Choi,Timothy E. McAlindon,Huan Li,Na Lu,Guanghua Lei,Yuqing Zhang +11 more
TL;DR: IACs, especially continuous Iacs, may be associated with an increased risk of knee ROA progression, and the associations of IACs initiation using a propensity-score matched cohort study and continuous IAC’s using marginal structural models with therisk of kneeROA progression were examined.
172
References
Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial
Jean-Yves Reginster,Jean-Yves Reginster,Rita Deroisy,Lucio C. Rovati,Richard L Lee,Eric Lejeune,Olivier Bruyère,Giampaolo Giacovelli,Yves Henrotin,Jane Dacre,Christiane Gossett +10 more
TL;DR: The long-term combined structure- modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis.
1.2K
Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.
Karel Pavelka,J. Gatterova,M. Olejarova,Stanislav Machacek,Giampaolo Giacovelli,Lucio C. Rovati +5 more
TL;DR: Long-term treatment with glucosamine sulfate retarded the progression of knee osteoarthritis, possibly determining disease modification.
Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip. The Rotterdam Study
Max Reijman,Huib A.P. Pols,Arjan P. Bergink,Johanna M. W. Hazes,J. N. Belo,Annet Lievense,Sita M A Bierma-Zeinstra +6 more
TL;DR: It is concluded that BMI is associated with the incidence and progression of knee osteoarthritis and a significant association between progression of osteoartritis and BMI was not found.
498
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
Clifton O. Bingham,J. Chris Buckland-Wright,Patrick Garnero,Stanley Cohen,Maxime Dougados,Silvano Adami,Daniel J. Clauw,Tim D. Spector,Jean-Pierre Pelletier,Jean Pierre Raynauld,Vibeke Strand,Lee S. Simon,Joan M Meyer,Gary A Cline,John F. Beary +14 more
TL;DR: Although risedronate did not improve signs or symptoms of OA, nor did it alter progression of Oa, a reduction in the level of a marker of cartilage degradation was observed and a sustained clinically relevant improvement in signs and symptoms was observed.
Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial
Maxime Dougados,Minh Vu Chuong Nguyen,L. Berdah,Bernard Mazières,Eric Vignon,Michel Lequesne +5 more
TL;DR: It is confirmed that the demonstration of a structure-modifying effect in hip OA is feasible, and shows, for the first time, that treatment with diacerein for 3 years has a significant structure- modifying effect as compared with placebo, coupled with a good safety profile.
343
Related Papers (5)
Roy D. Altman,E. Asch,Daniel Bloch,Giles G. Bole,David G. Borenstein,Kenneth D. Brandt,Wallace C. Christy,Cooke Td,Robert A. Greenwald,Marc C. Hochberg,David S. Howell,David L. Kaplan,William J. Koopman,Selden Longley,Henry J. Mankin,Dennis J. McShane,Thomas A. Medsger,Robert F. Meenan,William M. Mikkelsen,Roland W. Moskowitz,William A. Murphy,B. Rothschild,Mark R. Segal,Leon Sokoloff,Frederick Wolfe +24 more
Roy D. Altman,Graciela S. Alarcón,D. Appelrouth,Daniel Bloch,David G. Borenstein,Kenneth D. Brandt,C. Brown,Cooke Td,W W Daniel,D. Feldman,Robert A. Greenwald,Marc C. Hochberg,David S. Howell,Robert W. Ike,P. Kapila,David L. Kaplan,William J. Koopman,Catherine Marino,Eric V. McDonald,Dennis J. McShane,Thomas A. Medsger,B. A. Michel,William A. Murphy,T. Osial,Rosalind Ramsey-Goldman,Bruce M. Rothschild,Frederick Wolfe +26 more